2025
Estimated Theoretical Benefit of Aggressive LDL Lowering in Patients With Symptomatic Intracranial Atherosclerosis
Siegler J, Badillo Goicoechea E, Yaghi S, Morsi R, Arevalo A, Smith M, Kothari S, Desai H, Sehgal N, Rana R, Kellogg C, Jhaveri A, de Havenon A, Dunne T, Cameron K, Chaturvedi S, Ghannam M, Prabhakaran S, Coleman E, Brorson J, Mehendale R, Kass-Hout T. Estimated Theoretical Benefit of Aggressive LDL Lowering in Patients With Symptomatic Intracranial Atherosclerosis. Neurology 2025, 105: e213768. PMID: 40446174, DOI: 10.1212/wnl.0000000000213768.Peer-Reviewed Original ResearchConceptsProprotein convertase subtilisin/kexin type 9 inhibitorsIntracranial atherosclerotic diseasePrimary outcomeMyocardial infarctionStroke due to intracranial stenosisRecurrent strokeIntracranial stenosisPCSK9 inhibitor useClass IV evidenceCox proportional hazards regressionRecurrent cerebral infarctionSymptomatic intracranial atherosclerosisAggressive medical managementAssociated with lower ratesLow-density lipoprotein (LDLInterventional clinical trialsAtherosclerotic vascular eventsProportional hazards regressionSecondary analysisLDL improvementLipoprotein (LDLPreventing Recurrent StrokeIncidence rate differenceLDL reductionIV evidence
2024
Optimizing Clinical Trial Eligibility Design Using Natural Language Processing Models and Real-World Data: Algorithm Development and Validation
Lee K, Liu Z, Mai Y, Jun T, Ma M, Wang T, Ai L, Calay E, Oh W, Stolovitzky G, Schadt E, Wang X. Optimizing Clinical Trial Eligibility Design Using Natural Language Processing Models and Real-World Data: Algorithm Development and Validation. JMIR AI 2024, 3: e50800. PMID: 39073872, PMCID: PMC11319878, DOI: 10.2196/50800.Peer-Reviewed Original ResearchNon-small cell lung cancerCell lung cancerClinical trialsLung cancerEligibility criteriaTrial protocolInterventional clinical trialsClinical trial designProstate cancerMultiple myelomaBreast cancerEligible patientsClinical trial protocolsMount Sinai Health SystemCrohn's diseaseUlcerative colitisPatientsPatient identificationSinai Health SystemCancerNatural language processingClinical trial processDelay drug developmentTrial designNatural language processing pipeline
2023
Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review
Doernberg S, Arias C, Altman D, Babiker A, Boucher H, Creech C, Cosgrove S, Evans S, Fowler V, Fritz S, Hamasaki T, Kelly B, Leal S, Liu C, Lodise T, Miller L, Munita J, Murray B, Pettigrew M, Ruffin F, Scheetz M, Shopsin B, Tran T, Turner N, Williams D, Zaharoff S, Holland T, Patel R, King H, Kinamon T, Dai W, Geres H, Deckard N, Schuler C, Bunn I, Sharma S, Wickward C, Waller J, Wilson H, Mehigan M, Ghazaryan V, Raterman E, Samuel T, Lee M. Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review. Clinical Infectious Diseases 2023, 77: s295-s304. PMID: 37843115, PMCID: PMC10578051, DOI: 10.1093/cid/ciad565.Peer-Reviewed Original ResearchConceptsAntibacterial Resistance Leadership GroupMRSA bloodstream infectionsMethicillin-resistant Staphylococcus aureusBloodstream infectionsClinical trialsPediatric community-acquired pneumoniaInfection researchEnterococcal bloodstream infectionsOptimal vancomycin dosingOptimization of dosingRole of dalbavancinCommunity-acquired pneumoniaShort-course therapyInterventional clinical trialsVancomycin-resistant enterococciVancomycin dosingPositive infectionsNovel agentsLife measuresTreat infectionsClinical practiceNarrative reviewInfectionPositive bacteriaStaphylococcus aureus
2022
Homocysteine Levels and Clinical Outcomes in Schizophrenia—A Pilot Randomized Controlled Trial
Vedam V, Ghanta M, Kantipudi S, David D, Vijayalakshmi M, Nuthalapati P. Homocysteine Levels and Clinical Outcomes in Schizophrenia—A Pilot Randomized Controlled Trial. Journal Of Pharmacology And Pharmacotherapeutics 2022, 13: 284-292. DOI: 10.1177/0976500x221128649.Peer-Reviewed Original ResearchBrief Psychiatric Rating ScaleBrief Psychiatric Rating Scale scoresSchizophrenia patientsAbnormal Involuntary Movement Scale scorePsychiatric Rating ScaleEfficacy of olanzapineSafety of haloperidolHomocysteine levelsOlanzapine groupHaloperidol groupSchizophrenia treatmentPeripheral bloodOlanzapineRating ScalePilot randomized controlled trialHaloperidolSchizophreniaLevels of peripheral bloodTreatment outcomesScale scoreInterventional clinical trialsBlood homocysteine levelsRandomized Controlled TrialsClinical outcomesRight drug
2018
TQuest, A Web-Based Platform to Enable Precision Medicine by Linking a Tumor’s Genetic Defects to Therapeutic Options
Gershkovich P, Platt J, Knopf J, Tasoulis MK, Shi W, Pusztai L, Hatzis C. TQuest, A Web-Based Platform to Enable Precision Medicine by Linking a Tumor’s Genetic Defects to Therapeutic Options. JCO Clinical Cancer Informatics 2018, 2: 1-13. PMID: 30652574, DOI: 10.1200/cci.17.00120.Peer-Reviewed Original ResearchConceptsData acquisition layerFull-text indexAcquisition layerUser interfaceData layersPrototype web applicationWeb-based platformWeb applicationRelevance scoresSearch enginesSource codeSoftware toolsSearch resultsInterventional clinical trialsLabel dataClinical trialsTherapeutic optionsPlatformUS FoodMolecular abnormalitiesMetastatic breast cancerPotential therapeutic optionPotential treatment optionTumor DNA sequencingWeb-based modules
2017
Novel Metrics in the Longitudinal Evaluation of Pain Data in Sickle Cell Disease
Bakshi N, Smith M, Ross D, Krishnamurti L. Novel Metrics in the Longitudinal Evaluation of Pain Data in Sickle Cell Disease. The Clinical Journal Of Pain 2017, 33: 517-527. PMID: 27584817, DOI: 10.1097/ajp.0000000000000431.Peer-Reviewed Original ResearchConceptsMaximum daily painSickle cell diseasePain intensity dataChronic painCell diseasePain dataInterindividual variationMaximum daily pain scoresPatient-reported end pointsDaily pain scoresPain-free daysInterventional clinical trialsBurden of painPeriod of hospitalizationElectronic pain diaryDiary daysHealth care providersPain burdenPain scoresPain diaryPain intensityDaily painSCD patientsPain trendsClinical trials
2016
Publication and reporting of clinical trial results: cross sectional analysis across academic medical centers
Chen R, Desai NR, Ross JS, Zhang W, Chau KH, Wayda B, Murugiah K, Lu DY, Mittal A, Krumholz HM. Publication and reporting of clinical trial results: cross sectional analysis across academic medical centers. The BMJ 2016, 352: i637. PMID: 26888209, PMCID: PMC4768882, DOI: 10.1136/bmj.i637.Peer-Reviewed Original ResearchConceptsAcademic medical centerInterventional clinical trialsClinical trialsMedical CenterStudy completionPrimary completion dateClinical trial resultsReporting of resultsSectional analysisInterventional trialsProportion of trialsTrial resultsTrialsMonthsPhase IIManual reviewLead investigatorUnited StatesProportionRate of publicationReportingCompletionPatientsCenter
2009
A Phase I Study of Intravitreal Vascular Endothelial Growth Factor Trap-Eye in Patients with Neovascular Age-Related Macular Degeneration
Nguyen QD, Shah SM, Browning DJ, Hudson H, Sonkin P, Hariprasad SM, Kaiser P, Slakter JS, Haller J, V. D, Mieler WF, Chu K, Yang K, Ingerman A, Vitti RL, Berliner AJ, Cedarbaum JM, Campochiaro PA. A Phase I Study of Intravitreal Vascular Endothelial Growth Factor Trap-Eye in Patients with Neovascular Age-Related Macular Degeneration. Ophthalmology 2009, 116: 2141-2148.e1. PMID: 19700196, DOI: 10.1016/j.ophtha.2009.04.030.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overChoroidal NeovascularizationFemaleFluorescein AngiographyFollow-Up StudiesHumansInjectionsMacular DegenerationMaleMaximum Tolerated DoseReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsTomography, Optical CoherenceTreatment OutcomeVisual AcuityVitreous BodyConceptsVEGF Trap-EyeAge-related macular degenerationVascular endothelial growth factor (VEGF) Trap-EyeNeovascular age-related macular degenerationNeovascular AMDChoroidal neovascularizationOptical coherence tomographyFoveal thicknessIntravitreal injectionVisual acuityMacular degenerationMean increaseArea of CNVExcess foveal thicknessSingle intraocular injectionPrimary end pointSerious adverse eventsPhase III trialsHigh-dose groupInterventional clinical trialsActive choroidal neovascularizationNumber of patientsHuman immunoglobulin G (IgG) FcVEGF receptor 1VEGF family members
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply